Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 31, 2014

View Archived Issues

Clovis Oncology plans big year for 2014

Multiple pivotal phase III trials under way at Array BioPharma

Avanir Pharmaceuticals submits NDA for AVP-825 for migraine

Advanced Proteome Therapeutics provides update on modified proteins for cancer

Enrollment opened in phase II study of GLPG-0634 in Crohn's disease

FDA accepts NDA filing for budesonide foam for distal ulcerative colitis

Phase II trial of tivozanib in breast cancer discontinued

PCI Biotech awarded grant from the Research Council of Norway

Researchers at Bristol-Myers Squibb prepare new XIAP inhibitors for cancer

Amgen offers overview of fourth quarter 2013

Merck & Co. discloses novel agents for HIV infection

Novel antibodies claimed by OncoMed Pharmaceuticals for cancer

Japanese group discloses new antitumor agent

NeoGenomics launches 22 NeoTYPE genomic profiling tests for cancer

Amarantus and Boston University to evaluate test for early signs of neurodegenerative diseases

Drug developed for diabetes ameliorates experimental SMA

DSP and Edison Pharmaceuticals expand cooperation for mitochondrial disease

Asahi Kasei and Zosano discontinue development of Teribone transdermal patch

Eureka Therapeutics and Memorial Sloan-Kettering Cancer Center licenses anticancer MAb to Novartis

Amgen's RUTHERFORD-2 phase III trial of evolocumab in HeFH meets primary endpoints

AstraZeneca to join VIB and CD3 in development of MALT1 inhibitors

Unique HSP 90 inhibitor does not induce prosurvival heat shock response

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...